Inclusion of S-sepharose beads in the culture medium significantly improves recovery of secreted rBPI21 from transfected CHO-K1 cells

Protein Expression and Purification

Volumn 18, Issue 1, 2000, Pages 77-85

  Horwitz, Arnold H ^a   Carroll, Stephen F ^a   Williams, Robert E ^a   Liu, Pei Syan ^a  

^a XOMA Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CHO CELL; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; ION EXCHANGE CHROMATOGRAPHY; PRODUCT RECOVERY; PROTEIN PURIFICATION; RECOMBINANT PROTEIN; SCALE-UP;

NEGIBACTERIA;

EID: 0034141436     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1006/prep.1999.1163     Document Type: Article

References (23)

1. Elsbach P., Weiss J. Gallin J. I., Goldstein I. M., Snyderman R. Basic Principles and Clinical Correlates. 1992;603-636 Raven Press, New York.
2. Elsbach P., Weiss J. Bactericidal/permeability-increasing protein and host-defense against gram-negative bacteria and endotoxin. Curr. Opin. Immunol. 5:1993;103-107.
3. Ooi C. E., Weiss J., Elsbach P., Frangione B., Mannion B. A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein J. Biol. Chem. 262:1987;14891-14894.
4. Gray P. W., Flaggs G., Leong S. R., Gumina R. J., Ooi C. E., Elsbach P. Structural and functional correlations J. Biol. Chem. 264:1989;9505-9509.
5. Gazzano-Santoro H., Parent J. B., Grinna L., Horwitz A., Parsons T., Theofan G., Elsbach P., Weiss J., Conlon P. J. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect. Immun. 60:1992;4754-4761.
6. Weiss J., Elsbach P., Shu C., Castillo J., Grinna, Horwitz A., Theofan G. Human bactericidal/permeability-increasing protein and a recombinant N-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit TNF release induced by the bacteria. J. Clin. Invest. 3:1992;1122-1130.
7. Horwitz A. H., Leigh S. D., Abrahamson S., Gazzano-Santoro H., Liu P.-S., Williams R. E., Carroll S. F., Theofan G. Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein. Protein Express. Purif. 8:1996;28-40.
8. Giroir B. P., Carroll S. F., Scannon P. J. Bactericidal/permeability-increasing protein (BPI): Structure, function, and clinical applications. Vincent J.-L. Yearbook of Intensive Care and Emergency Medicine. 1998;15 Springer, Buffalo Grove.
9. Mulligan R. C., Berg P. Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase. Proc. Natl. Acad. Sci. USA. 78:1981;2072-2076.
10. Better M., Bernhard S. L., Fishwild D. M., Nolan P. A., Bauer R. J., Kung A. H. C., Carroll S. F. Gelonin analogs with engineered cysteine residues for antibody immunoconjugates with unique properties. J. Biol. Chem. 269:1994;9644-9650.
11. Goff D., Carroll S. F. Substituted 2-iminothiolanes: Reagents for the preparation of disulfide cross-linked conjugates with increased stability. Bioconjugate Chem. 1:1990;381-386.
12. White M. L., Ma J. K., Birr C. A., Trown P. W., Carroll S. F. Measurement of bactericidal/permeability-increasing protein in human body fluids by sandwich ELISA. J. Immunol. Methods. 167:1994;227-236.
13. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
14. Hook M., Kjellen L., Johansson S., Robinson J. Cell-surface glycosaminoglycans. Annu. Rev. Biochem. 53:1984;847-869.
15. Abrahamson S. L., Wu H. M., Williams R. E., Der K., Ottah N., Little R., Gazzano-Santoro H., Theofan G., Bauer R., Leigh S., Orme A., Horwitz A. H., Carroll S. F, Dedrick R. L. Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein: Implications in biological activity. J. Biol. Chem. 272:1997;2149-2155.
16. 23). J. Biol. Chem. 269:1994;1865-1872.
17. Hassell J. R., Kimura J. H., Hascall V. C. Proteoglycan core protein families. Annu. Rev. Biochem. 55:1986;539-567.
18. Stirpe F., Olsnes S., Pihl A. Gelonin, a new inhibitor of protein synthesis, is non toxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J. Biol. Chem. 255:1980;6947-6953.
19. Lugo N. Aseptic processing of biopharmaceuticals. Groves M. J., Murty A. Aseptic Pharmaceutical Manufacturing II: Application for the 1990s. 1995;245-289 Interpharm Press, Buffalo Grove.
20. Reff M. E. High level production of recombinant immunoglobulins in mammalian cells. Curr. Opin. Biotechnol. 4:1993;573-576.
21. Esko J. D., Stewart T. E., Taylor W. H. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc. Natl. Acad. Sci. USA. 82:1985;3197-3201.
22. Bauer R. J. The role of liver and kidney on the pharmacokinetics of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein. Pharmaceut. Res. 14:1996;224-229.
23. Theofan G., Horwitz A. H., Williams R. E., Liu P.-S., Chan I., Birr C., Carroll S., Mészáros K., Parent J. B., Kasler H., Aberle S., Trown P. W., Gazzano-Santoro H. An amino-terminal fragment of human lipopolysaccharide binding protein retains binding but not CD14-stimulatory activity. J. Immunol. 152:1994;3623-3629.